Australia Identifies HTA Challenges Posed By Emerging Technologies

Pharmaceutical industry stakeholders have expressed concern over the lack of clarity about the available pathways for assessing emerging health technologies such as gene and gene modified cell therapies, as well as problems with funding arrangements.

Funding
Cost will be a key factor in assessing whether new technologies should be subsidized • Source: Shutterstock

Emerging technologies such as advanced therapies, tumor-agnostic therapies, antibody-drug conjugates and microbiome-based therapies are likely to pose a challenge for existing health technology assessment (HTA), funding and subsidy pathways, according to a draft paper published by the Australian government.

“The challenges to HTA vary depending on the technology,” the paper says, noting that therapies that target specific gene variants...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Health Technology Assessment

Faster HTA Reviews & Pricing Reform Could Help Fix Canada’s Drug Access Woes

 

Canadian politicians must “move quickly” to introduce policies that will speed up access to medicines, such as by broadening criteria for the temporary reimbursement of medicines, the Canadian Chamber of Commerce says.

UK Approves Biogen’s Qalsody After England Revises Reimbursement Approach

 

Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.

England’s NICE Hunts For New Chief As Sam Roberts Prepares To Step Down

 

Sam Roberts, chief executive of the health technology assessment institute, NICE, will step down from her role at the end of the year. The agency is now on the lookout for a new leader, who will be the fourth in its history.

Leqembi Facing 15% Price Cut In Japan

 
• By 

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.

More from Market Access